Charles Gbadouwey, MD
Pulmonary Disease · Monroe, LANPI 1043255177
Payments from drug & device makers
Across 802 payments — averaging $44.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$20K
- AstraZeneca$4K
- GSK$2K
- Jazz Pharmaceuticals Inc.$1K
- Boehringer Ingelheim$1K
- Sanofi$759
- plus $6K from 31 others
What the payments were for
- Consulting fees$4,80713%
- Speaking & faculty fees$12,71736%
- Travel & lodging$1,9225%
- Food & beverage$14,69341%
- Education$1,5324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 102 | $20,489 |
| AstraZeneca | 171 | $3,871 |
| GSK | 138 | $2,090 |
| Jazz Pharmaceuticals Inc. | 36 | $1,443 |
| Boehringer Ingelheim | 63 | $1,262 |
| Sanofi | 39 | $759 |
| Harmony Biosciences LLC | 25 | $692 |
| Regeneron Healthcare Solutions, Inc. | 30 | $636 |
| Actelion Pharmaceuticals US, Inc. | 16 | $518 |
| Philips North America LLC | 26 | $487 |
| Insmed, Inc. | 14 | $382 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $338 |
| Amgen | 15 | $306 |
| United Therapeutics Corporation | 13 | $283 |
| Grifols USA, LLC | 13 | $242 |
| Verona Pharma, Inc. | 11 | $224 |
| Sunovion Pharmaceuticals Inc. | 12 | $208 |
| Lilly USA, LLC | 6 | $202 |
| Baxter Healthcare | 6 | $142 |
| Advanced Respiratory, Inc | 8 | $128 |
| Teva Pharmaceuticals USA, Inc. | 7 | $120 |
| Sanofi-aventis U.S. LLC | 2 | $113 |
| Genentech USA, Inc. | 8 | $112 |
| ANI Pharmaceuticals, Inc. | 4 | $111 |
| Optinose US, Inc. | 5 | $84 |
| Circassia Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Shire North American Group Inc | 3 | $49 |
| Gilead | 2 | $37 |
| Viatris Specialty LLC | 2 | $34 |
| Resmed Corp | 2 | $29 |
| CSL Behring | 1 | $27 |
| Novartis | 1 | $22 |
| Medtronic | 1 | $20 |
| Biogen | 1 | $17 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,670 in reported general payments places this provider in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 194 | $164,977 |
| WakixPitolisant Hcl | 14 | $109,320 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $56,262 |
| Spiriva RespimatTiotropium Bromide | 78 | $49,246 |
| EliquisApixaban | 40 | $34,634 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $28,673 |
| MounjaroTirzepatide | 23 | $26,677 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $19,748 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $13,693 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $12,216 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,881 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 236 | $7,036 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $6,957 |
| Roflumilast | 19 | $4,375 |
| Varenicline Tartrate | 21 | $4,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $2,090 | $214,747310 claims |
| Harmony Biosciences LLCWakix | $692 | $109,32014 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,262 | $68,994107 claims |
| AstraZenecaBreztri Aerosphere | $3,871 | $56,26270 claims |
| Lilly USA, LLCMounjaro | $202 | $26,67723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Monroe
- Thomas GullattMonroe$12K
- David GreenShreveport$2M
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Juzar AliNew Orleans$775K
- Hollis O NealBaton Rouge$682K
- Andrea EspinozaHouma$655K
- Ramsy AbdelghaniNew Orleans$474K
- Bennett DeboisblancNew Orleans$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.